HOPA 2021: Investigational Oncology Drugs Could Have Significant Impact on Patients
As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.
As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape. In an upcoming session at the Hematology/Oncology Pharmacists Association (HOPA) virtual 2021 conference, which runs from April 12 to 17, HOPA President-Elect Heidi Finnes, PharmD, BCOP, FHOPA, will discuss investigational cancer treatments.
In a pre-conference interview with Pharmacy Times, Finnes said she tried to select drugs to discuss in the session based on the current landscape of medications popular during the COVID-19 pandemic as many patients have been unable to come to hospitals or clinics for treatment. She also chose treatments with novel mechanisms.
“I think one of the most exciting drugs is actually a clinical trial that we took part in at my institution of a hematology medication called camidanlumabi tesirine, and it’s an antibody drug conjugate for relapsed [or] refractory hodgkin’s lymphoma,” Finnes said.
Finnes also discussed what attendees can look forward to at the conference, and said she always enjoys the networking opportunities and leaves the conference feeling inspired.
